TITLE

Diabetes

PUB. DATE
July 1999
SOURCE
Geriatrics;Jul99, Vol. 54 Issue 7, p12
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the approval of rosiglitazone maleate (Avandia) for the treatment of type 2 diabetes as monotherapy or in combination with metformin by the United States Food and Drug Administration. How rosiglitazone works in the body; Effects of the drug on blood sugar levels; Recommended starting dosage.
ACCESSION #
2315593

 

Related Articles

  • The heartbreaking story of Avandia. Safyan, Susan // Alive: Canada's Natural Health & Wellness Magazine;Oct2007, Issue 300, p64 

    The article reports on the cardiovascular risk of Avandia, a drug for Type 2 Diabetes. Food and Drug Administration's (FDA) Office of Surveillance and Epidemiology (OSE) in the U.S. suggest to the health panelist the immediate withdrawal of the drug from the market after their thorough...

  • Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes.  // Formulary;Feb2010, Vol. 45 Issue 2, p43 

    Despite the availability of multiple classes of glucose-lowering agents to treat type 2 diabetes mellitus, glycemic control often remains inadequate, with hemoglobin (Hb) A|c values above the treatment goal of 7%. One newer class of agents, the glucagon-like peptide (GLP-1) receptor agonists,...

  • Bromocriptine in Diabetes Mellitus - A Review. Pandita, Aakriti; Azher, Idrees // Asian Student Medical Journal;2013, Vol. 13 Issue 6, p1 

    The article presents information on the approval of the drug QR-bromocriptine by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus. It mentions that the drug is an antidiabetic that helps in reducing plasma glucose, triglycerides and cardiovascular events....

  • A 1-Year Multicenter Randomized Double-Blind Comparison of Repaglinide and Glyburide for the Treatment of Type 2 Diabetes. Wolffenbuttel, Bruce H. R.; Landgraf, Rudiger // Diabetes Care;Mar1999, Vol. 22 Issue 3, p463 

    Presents a study which compared the efficacy and safety of Repaglinide with glyburide in a 1-year randomized double-blind study of outpatients with type 2 diabetes. Research design and methods; Results; Conclusions.

  • Two new diabetes drugs on the market.  // Cardiology Today;Mar2012, Vol. 15 Issue 3, p35 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of two drugs indicated for the treatment of type 2 diabetes.

  • FDA restricts Rezulin use.  // Drug Store News;7/19/99, Vol. 21 Issue 11, pCP10 

    Reports the restriction made by the United States Food and Drug Administration (FDA) on the use of Warner-Lambert Co.'s Rezulin and revoked the drug's approval for use as monotherapy of patients with type II diabetes. Condition imposed by the FDA on Warner-Lambert concerning the use of the...

  • Colesevelam: A novel drug for comorbid diabetes and dyslipidemia. Dixit, Alok; Pandey, Pinki // Chronicles of Young Scientists;Oct-Dec2012, Vol. 3 Issue 4, p312 

    The article discusses the approval of the colesevelam hydrochloride by the U.S. Food and Drug Administration for type 2 diabetes mellitus and dyslipidemia. It mentions that the drug is approved as adjunctive treatment for T2DM in combination with sulfonylurea, metformin, and insulin therapy. It...

  • FDA approved liraglutide to treat type 2 diabetes.  // Endocrine Today;Feb2010, Vol. 8 Issue 2, p2 

    The article reports that the U.S. Food and Drugs Administration (FDA) approved the use of liraglutide to treat type 2 diabetes.

  • Linagliptin now FDA-approved for type 2 diabetes.  // Endocrine Today;Jun2011, Vol. 9 Issue 6, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) approved the use of Linagliptin to improve blood glucose control in adult patients with type 2 diabetes.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics